 Home > Active Ingredient News > Drugs Articles > Novo Nordisk's IL-6 inhibitor Ziltivekimab clinical application accepted by NMPA

Novo Nordisk's IL-6 inhibitor Ziltivekimab clinical application accepted by NMPA

 Last Update: 2021-08-28
 Source: Internet
 Author: User

Tags

congenital liver disease

drug disease interaction

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently (August 12), Novo Nordisk's IL-6 inhibitor Ziltivekimab clinical application was accepted by NMPA (JXSL2101092)

Ziltivekimab

Ziltivekimab is a fully human monoclonal antibody that can reduce systemic inflammation by inhibiting IL-6, and has undergone long-acting transformation to extend its half-life.

IL-6 (Interleukin-6) is a key innate immune cytokine responsible for performing a wide range of physiological functions including host defense, immune cell regulation, proliferation and differentiation

Currently, Novo Nordisk is exploring the use of Ziltivekimab to treat cardiovascular diseases

Clinical outcome

In May of this year, Novo Nordisk disclosed the RESCUE II clinical results of Ziltivekimab in the treatment of patients with high-risk atherosclerotic chronic kidney disease (CKD) at ACC 2021

The Lancet

It is understood that half of the deaths of CKD patients are due to cardiovascular-related complications, and atherosclerosis is one of the main causes of CKD

Other related

In June last year, Novo Nordisk announced the acquisition of AstraZeneca’s subsidiary Corvidia Therapeutics for a cash advance of US$725 million, and a total of US$2.

As a result, Novo Nordisk has obtained Corvidia's main drug candidate Ziltivekimab

Reference materials:

References: References:

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

RU 58841 CAS 154992-24-2 RU58841 Powder Bulk RU-58841 For Hair Growth and Anti Hair Loss

CAS No.: 154992-24-2

Pharmacy Grade

$1-1.2/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.